Thursday, May 28, 2020 | Last Update : 01:13 PM IST

64th Day Of Lockdown

Maharashtra54758169541792 Tamil Nadu177289342128 Delhi152577264303 Gujarat148297139915 Rajasthan76804341172 Madhya Pradesh70243689305 Uttar Pradesh67243824177 West Bengal40091486283 Andhra Pradesh3117206558 Bihar300680014 Karnataka240576245 Punjab2106191840 Telangana1991128457 Jammu and Kashmir175983324 Odisha15937337 Haryana130582416 Kerala9645426 Assam683634 Jharkhand4261534 Uttarakhand400644 Chhatisgarh360790 Chandigarh2781874 Tripura2321650 Himachal Pradesh223634 Goa67280 Puducherry49170 Manipur3940 Meghalaya20121 Nagaland900 Arunachal Pradesh210 Mizoram110 Sikkim100

WHO Solidarity trial testing antiviral drug remdesivir, as it could stop coronavirus from replicating

PTI
Published : Apr 14, 2020, 1:51 pm IST
Updated : Apr 14, 2020, 1:51 pm IST

In an observational study, 68 per cent or two out of three patients after treatment with the drug did not require ventilator support

In this March 2020 photo provided by Gilead Sciences, rubber stoppers are placed onto filled vials of the investigational drug remdesivir at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Photo | AP)
 In this March 2020 photo provided by Gilead Sciences, rubber stoppers are placed onto filled vials of the investigational drug remdesivir at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Photo | AP)

New Delhi: The Indian Council of Medical Research on Monday said antiviral drug remdesivir, which was used during the Ebola outbreak, may be highly effective in stopping the replication mechanism of SARS-CoV-2 that causes COVID-19.

The ICMR said research on its efficacy in the treatment of COVID-19 is a part of WHO's "Solidarity Trial".

According to a recently published study in the New England Journal of Medicine, two out of three critically ill coronavirus infected patients who were on oxygen support or on ventilators showed signs of improvement when they were administered remdesivir.

Commenting on the study, Head of Epidemiology and Communicable diseases at ICMR Raman R Gangakhedkar said that drug which was used against Ebola virus, according to the researchers, hinders the reproduction of coronavirus which is why they believe that it could be effective in COVID-19 treatment.

"A recently reported study on use of remdesivir for COVID-19 treatment is not a clinical trial, but an observational study which found that 68 per cent or two out of three patients after treatment with the drug did not require ventilator support or their need for oxygen support reduced. We will come to know of further developments through the WHO Solidarity Trial, which has an arm which is looking into this," he said.

He further said that remdesivir, developed by Gilead Sciences Inc, is not presently available in the country and the government is working on to see if  any pharmaceutical company can manufacture it.

Tags: coronavirus (covid-19), ebola, sars-cov-2, indian council of medical research (icmr), new england journal of medicine, remdesivir, who solidarity trial